Review



plasma hepo protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems plasma hepo protein
    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of <t>hEPO</t> mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), <t>and</t> <t>MCP-1</t> (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Plasma Hepo Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 180 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+hepo+protein/bio_rxiv__64898__2026__04__07__716828-200-6-10?v=R%26D+Systems
    Average 95 stars, based on 180 article reviews
    plasma hepo protein - by Bioz Stars, 2026-07
    95/100 stars

    Images

    1) Product Images from "A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity"

    Article Title: A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity

    Journal: bioRxiv

    doi: 10.64898/2026.04.07.716828

    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Figure Legend Snippet: (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.

    Techniques Used: Expressing



    Similar Products

    plasma hepo protein  (R&D Systems)
    95
    R&D Systems plasma hepo protein
    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of <t>hEPO</t> mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), <t>and</t> <t>MCP-1</t> (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Plasma Hepo Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+hepo+protein/bio_rxiv__64898__2026__04__07__716828-200-6-10?v=R%26D+Systems
    Average 95 stars, based on 1 article reviews
    plasma hepo protein - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.

    Journal: bioRxiv

    Article Title: A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity

    doi: 10.64898/2026.04.07.716828

    Figure Lengend Snippet: (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.

    Article Snippet: ELISA kits were used to quantify plasma hEPO protein (DEP00; R&D Systems, Minneapolis, MN, USA) and MCP-1 (BMS631INST; Thermo Fisher Scientific, Waltham, MA, USA).

    Techniques: Expressing